Exchange: AMEX Sector: Healthcare Industry: Biotechnology
-0.07% $0.280
America/New_York / 17 apr 2024 @ 15:55
FUNDAMENTALS | |
---|---|
MarketCap: | 15.47 mill |
EPS: | -0.510 |
P/E: | -0.550 |
Earnings Date: | May 10, 2024 |
SharesOutstanding: | 55.22 mill |
Avg Daily Volume: | 2.65 mill |
RATING 2024-04-17 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Strong Buy | |
P/E: | Neutral | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | |||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.550 | sector: PE -4.07 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -0.550 | industry: PE -5.55 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.133 (-147.40%) $-0.413 |
Date: 2024-04-17 |
Expected Trading Range (DAY) |
---|
$ 0.225 - 0.335 ( +/- 19.64%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-11 | Blum Susan | Buy | 0 | |
2024-03-16 | Cystic Fibrosis Foundation | Sell | 0 | Common Stock, par value $0.0001 per share |
2024-03-16 | Cystic Fibrosis Foundation | Sell | 21 635 000 | Series X Preferred Stock |
2024-03-16 | Cystic Fibrosis Foundation | Sell | 10 817 500 | Warrant to purchase common stock |
2024-03-16 | Cystic Fibrosis Foundation | Sell | 4 778 265 | Warrant to purchase common stock |
INSIDER POWER |
---|
-67.56 |
Last 91 transactions |
Buy: 9 333 285 | Sell: 39 545 482 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.280 (-0.07% ) |
Volume | 0.128 mill |
Avg. Vol. | 2.65 mill |
% of Avg. Vol | 4.83 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.